Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:TENK TenX Keane Acquisition (TENK) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsHeadlinesOwnershipShort InterestTrends About TenX Keane Acquisition Stock (NASDAQ:TENK) 30 days 90 days 365 days Advanced Chart Ad Paradigm PressMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840. Click here to see the details because there’s not much time to prepare. Get TenX Keane Acquisition alerts:Sign Up Key Stats Today's Range$1.03▼$1.1750-Day Range$1.62▼$40.5052-Week Range$9.54▼$49.00Volume60,237 shsAverage Volume65,453 shsMarket Capitalization$7.19 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTenX Keane Acquisition does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on target businesses operating in Asia, excluding companies located or operating in mainland China, Hong Kong, or Macau. TenX Keane Acquisition was incorporated in 2021 and is based in New York, New York.Read More… Musk’s new company could top a trillion? (Ad)The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840. Click here to see the details because there’s not much time to prepare. Receive TENK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TenX Keane Acquisition and its competitors with MarketBeat's FREE daily newsletter. Email Address TENK Stock News HeadlinesCitius Oncology Inc (CTOR)October 17 at 5:57 PM | investing.comCitius Pharmaceuticals, Inc.: Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.August 14, 2024 | finanznachrichten.deThe real reason Elon is fully endorsing TrumpElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. October 17, 2024 | Porter & Company (Ad)Citius Pharmaceuticals, Inc.: Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.August 6, 2024 | finanznachrichten.deTenX Keane Acquisition Shares Rise After Merger ApprovalAugust 5, 2024 | marketwatch.comCitius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business UpdateFebruary 14, 2024 | finance.yahoo.comTenX Keane Acquisition Announces Contribution to Trust Account in Connection with Extension Amendment ProposalJanuary 10, 2024 | finance.yahoo.comTenX Keane Acquisition (TENK)October 31, 2023 | investing.comSee More Headlines Company Calendar Today10/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorUnclassified Industry Holding & other investment offices Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TENK CUSIPN/A CIK1851484 Webwww.tenxkeane.com Phone347-627-0058FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares6,653,000Free Float5,129,000Market Cap$7.19 million OptionableNot Optionable BetaN/A 10 Best Stocks to Own in 2025Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free Report This page (NASDAQ:TENK) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMassive trading opportunity begins by October 21 October 21 could spark a mania among “next-generation” AI stocks. That’s the newest prediction from a Wall Str...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TenX Keane Acquisition Please log in to your account or sign up in order to add this asset to your watchlist. Share TenX Keane Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.